- Home
- ESEA vs CTNM Comparison
ESEA vs CTNM Comparison
Compare ESEA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESEA | CTNM |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.2M | 489.4M |
| IPO Year | 2005 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ESEA | CTNM |
|---|---|---|
| Price | $71.32 | $12.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $62.00 | $19.00 |
| AVG Volume (30 Days) | 65.4K | ★ 160.2K |
| Earning Date | 06-17-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.74 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $43.60 | $3.57 |
| 52 Week High | $78.76 | $16.33 |
Technical Indicators
Market Signals| Indicator | ESEA | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 42.71 |
| Support Level | $52.53 | $11.62 |
| Resistance Level | $71.86 | $13.26 |
| Average True Range (ATR) | 2.57 | 0.75 |
| MACD | 0.39 | -0.13 |
| Stochastic Oscillator | 86.79 | 30.61 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.